Please see package insert for additional information and possible updates. The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh
Inc. nor any other party involved in the preparation of this program shall be
liable for any special, consequential, or exemplary damages resulting in whole
or part from any user's use of or reliance upon this material. PLEASE READ THE
DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING
THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE
DISCLAIMER. [ Read the disclaimer
| <<Back |
New drug index
These highlights do not include all the information needed to use
BEPREVE™ (bepotastine besilate ophthalmic solution) 1.5% safely and
effectively. See full prescribing information for BEPREVE™.
BEPREVE™ (bepotastine besilate ophthalmic solution) 1.5%
Initial U.S. Approval: 2009
BEPREVE™ (bepotastine besilate ophthalmic solution) 1.5% is a sterile,
topically administered drug for ophthalmic use. Each mL of BEPREVE™
contains 15 mg bepotastine besilate.
Bepotastine besilate is designated chemically as (+) -4-[[(S)-p-chloro-alpha
-2-pyridylbenzyl]oxy]-1-piperidine butyric acid monobenzenesulfonate.
The most common adverse reaction occurring in approximately 25%
of patients was a mild taste following instillation. Other
adverse reactions which occurred in 2-5% of subjects were eye
irritation, headache, and nasopharyngitis.
To report SUSPECTED ADVERSE REACTIONS, contact ISTA
Pharmaceuticals, Inc. at 1-877-788-2020, or FDA at
1-800-FDA-1088 or www.fda.gov/medwatch.